In this article recently published in Science, the authors performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity.

In this nice review recently published in Lancet Neurology, the authors summarised the evidence for COVID-19 putative disease mechanisms, and suggested a framework for investigating patients with suspected COVID-19-associated neurological disease to support clinico-epidemiological, disease mechanistic, and treatment studies.

In this case series study, recently published in Lancet, the authors aimed to provide a clinicopathological report of severe COVID-19 cases by documenting histopathological changes and evidence of SARS-CoV-2 tissue tropism.

The objective of this retrospective cohort study was to compare the rate of ischaemic stroke between patients with COVID-19 and patients with influenza, a respiratory viral illness previously associated with stroke.

The objective of this prospective, open-label, randomised clinical trial, was to evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalised with COVID-19.

The objective of this case-series study, recently published in JAMA Neurology, was to report the neurological manifestations of children with COVID-19 who presented with SARS-CoV-2 infection and neurological symptoms to Great Ormond Street Hospital for Children (London, UK) between March 1, 2020, and May 8, 2020.

The objective of this multicentre cohort study, recently published in JAMA Internal Medicine, was to assess factors associated with death and to examine inter-hospital variation in treatment and outcomes for patients with COVID-19.

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

In this study recently published in the New England Journal of Medicine, the authors conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with candidate vaccine mRNA-1273 (which encodes the stabilised prefusion SARS-CoV-2 spike protein) in a dose of 25 μg, 100 μg, or 250 μg.

In this controlled, open-label trial recently published in the New England Journal of Medicine, the authors randomly assigned patients who were hospitalised with COVID-19 to receive either oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or usual care.

In celebration of World Brain Day 2020, the European Federation of Neurological Associations (EFNA) has published the results of its recent survey on stigma and neurological disorder. According to the World Health Organisation, stigma is a major cause of discrimination… Continue Reading

Professor Tissa Wijeratne and Professor Wolfgang Grisold have teamed up on an expert article for the World Brain Day "Move together to End Parkinson's Disease".

On this World Brain Day, watch interviews with specialists and patients regarding Parkinson´s Disease.

The main objective of World Brain Day is to increase public awareness and promote advocacy related to brain health.

EAN Clinical Fellowship